Terms: = Uterine cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Diagnosis
6 results:
1. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract] [Full Text] [Related]
2. Serum expression of tumor marker CA242 in patients with different gynecological diseases.
Zhu J; Li H
Lab Med; 2023 Nov; 54(6):613-617. PubMed ID: 37035887
[TBL] [Abstract] [Full Text] [Related]
3. Cytological features of mesonephric-like adenocarcinoma of the uterine corpus.
Seo Y; Park E; Kim HS
Diagn Cytopathol; 2023 May; 51(5):294-306. PubMed ID: 36756667
[TBL] [Abstract] [Full Text] [Related]
4. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract] [Full Text] [Related]
5. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.
Pretorius RG; Peterson P; Azizi F; Burchette RJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1260-5. PubMed ID: 17074547
[TBL] [Abstract] [Full Text] [Related]
6. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
Beresford SA; Weiss NS; Voigt LF; McKnight B
Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
[TBL] [Abstract] [Full Text] [Related]
